0001387131-11-001058.txt : 20110609 0001387131-11-001058.hdr.sgml : 20110609 20110609171947 ACCESSION NUMBER: 0001387131-11-001058 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20110609 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20110609 DATE AS OF CHANGE: 20110609 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Adamis Pharmaceuticals Corp CENTRAL INDEX KEY: 0000887247 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 820429727 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-26372 FILM NUMBER: 11903845 BUSINESS ADDRESS: STREET 1: 2658 DEL MAR HEIGHTS RD STREET 2: #555 CITY: DEL MAR STATE: CA ZIP: 92014 BUSINESS PHONE: (858) 401-3984 MAIL ADDRESS: STREET 1: 2658 DEL MAR HEIGHTS RD STREET 2: #555 CITY: DEL MAR STATE: CA ZIP: 92014 FORMER COMPANY: FORMER CONFORMED NAME: CELLEGY PHARMACEUTICALS INC DATE OF NAME CHANGE: 19950615 8-K 1 adamis-8k_060911.htm CURRENT REPORT adamis-8k_060911.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
 
 
FORM 8-K
 
 
CURRENT REPORT
 
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
Date of report (Date of earliest event reported):  June 9, 2011
 
 
ADAMIS PHARMACEUTICALS CORPORATION
(Exact Name of Registrant as Specified in Charter)
 
Delaware
  
0-26372
  
82-0429727
(State or other jurisdiction
of incorporation)
  
(Commission File Number)
  
(IRS Employer
Identification No.)
         
         
  11455 El Camino Real, Suite 310
San Diego, CA
        
92130
 (Address of Principal Executive Offices)       (Zip Code)
         
Registrant’s telephone number, including area code:  (858) 997-2400
 
2658 Del Mar Heights Road, #555
Del Mar, CA
 
(Former name or Former Address, if Changed Since Last Report.)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 
 
 

Item 5.02            Departure of Directors of Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
 
Richard L. Aloi, who is a director of Adamis Pharmaceuticals Corporation (the “Company”) and is President of its Adamis Laboratories, Inc. subsidiary, notified the Company on June 9, 2011 that in order to further the goal of having a majority of the board of directors consist of independent non-employee directors, he was resigning as a director of the Company and all direct and indirect subsidiaries of the Company of which he was a director.  Mr. Aloi is not resigning as an officer or employee of the Company and will remain the President of Adamis Laboratories.

                                                   
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
   
ADAMIS PHARMACEUTICALS CORPORATION
     
     
Dated:  June 9, 2011   
By:
/s/ Robert O. Hopkins
   
Name:
 Robert O. Hopkins
   
Title:
 Chief Financial Officer